Leila Godfrey
Overview
Explore the profile of Leila Godfrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waerlop G, Leroux-Roels G, Pagnon A, Begue S, Salaun B, Janssens M, et al.
J Immunol Methods
. 2023 Nov;
523:113584.
PMID: 37918618
The magnitude and quality of cell-mediated immune responses elicited by natural infection or vaccination are commonly measured by Interferon-ɣ (IFN-ɣ) Enzyme-Linked ImmunoSpot (ELISpot) and Intracellular Cytokine Staining (ICS). To date,...
2.
Lee M, Bell C, Rubio Garcia A, Godfrey L, Pekalski M, Wicker L, et al.
Discov Immunol
. 2023 Aug;
2(1):kyad012.
PMID: 37649552
Human CD56 natural killer (NK) cells represent a small subset of CD56 NK cells in circulation and are largely tissue-resident. The frequency and number of CD56 NK cells in blood...
3.
Yin Z, Chen J, Lu Y, Wang B, Godfrey L, Mentzer A, et al.
Cell Rep
. 2023 May;
42(5):112470.
PMID: 37141092
Most existing studies characterizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell responses are peptide based. This does not allow evaluation of whether tested peptides are processed and presented...
4.
Foster W, Newman J, Thakur N, Spencer A, Davies S, Woods D, et al.
Immunol Cell Biol
. 2023 Mar;
101(6):479-488.
PMID: 36975169
Effective vaccines have reduced the morbidity and mortality caused by severe acute respiratory syndrome coronavirus-2 infection; however, the elderly remain the most at risk. Understanding how vaccines generate protective immunity...
5.
Voysey M, Flaxman A, Aboagye J, Aley P, Belij-Rammerstorfer S, Bibi S, et al.
Clin Exp Immunol
. 2023 Feb;
211(3):280-287.
PMID: 36729167
The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following...
6.
Foster W, Lee J, Thakur N, Newman J, Spencer A, Davies S, et al.
Cell Rep Med
. 2022 Dec;
3(12):100845.
PMID: 36455555
Emergence from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been facilitated by the rollout of effective vaccines. Successful vaccines generate high-affinity plasma blasts and long-lived protective memory...
7.
Zhang J, Hamey F, Trzupek D, Mickunas M, Lee M, Godfrey L, et al.
Nat Commun
. 2022 Nov;
13(1):7324.
PMID: 36443294
Despite early clinical successes, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) immunotherapy remain only partly understood. Here we examine the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2)...
8.
Mentzer A, OConnor D, Bibi S, Chelysheva I, Clutterbuck E, Demissie T, et al.
Nat Med
. 2022 Oct;
29(1):147-157.
PMID: 36228659
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with vaccine efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 vaccine efficacy...
9.
Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, et al.
Clin Infect Dis
. 2022 Oct;
76(2):201-209.
PMID: 36196614
Background: People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)....
10.
Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J, et al.
JCI Insight
. 2022 Feb;
7(7).
PMID: 35192543
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male...